Amicus Prices IPO

Amicus Therapeutics Inc., a Cranbury, N.J.-based drug company focused on genetic diseases like Fabry disease, priced 5 million common shares at $15 per share ($14-$16 range), for an IPO take of approximately $60 million. The offering gave Amicus a market cap of approximately $333 million, but that fell as the stock finished its first day of trading down 4 percent. Morgan Stanley and Merrill Lynch served as co-lead underwriters. Amicus had raised around $146 million in total VC funding, including a $60 million Series D infusion late last year. Backers include New Enterprise Associates (26.3% pre-IPO stake), Frazier Healthcare Ventures (15.2%), Prospect Venture Partners (13.2%), CHL Medical Partners (12.4%), Canaan Partners (12.1%), Quaker BioVentures (8.3%), Och-Ziff Capital Management, Palo Alto Investors and Radius Ventures.